| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Revenue | $16.9M | -1.7% |
| R&D Expense | $5.6M | -16.0% |
| SG&A Expense | $45.8M | +7.4% |
| Operating Income | -$90.8M | -11.0% |
| Net Income | -$78.6M | -18.8% |
| EPS (Basic) | -$0.34 | -21.4% |
| EPS (Diluted) | -$0.34 | -21.4% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $189.4M | -36.5% |
| Accounts Receivable | $2.4M | -8.1% |
| Inventory | $4.5M | +18.2% |
| Current Assets | $203.7M | -47.3% |
| Total Assets | $583.9M | -10.2% |
| Current Liabilities | $24.4M | -73.4% |
| Long-term Debt | $67.1M | -1.5% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$57.4M | -6.8% |
| Capital Expenditures | $51.1M | -6.2% |
| Investing Cash Flow | -$51.8M | -145.4% |
| Financing Cash Flow | -$7.4M | -3795.2% |
| Free Cash Flow | -$108.5M | -0.3% |
| Total Liabilities |
| $94.5M |
| +1.6% |
| Stockholders' Equity | $489.5M | -12.2% |